Erythema multiforme exudativum (Stevens-Johnson syndrome) following sodium diphenylhydantoin therapy.
D000293:Adolescent; D000367:Age Factors; D001285:Atropine / Q000627:therapeutic use; D003228:Conjunctiva / Q000601:surgery; D003261:Contact Lenses; D003320:Corneal Ulcer / Q000139:chemically induced / Q000188:drug therapy; D004338:Drug Combinations; D005143:Eyelids / Q000601:surgery; D006801:Humans; D008297:Male; D008747:Methylcellulose / Q000627:therapeutic use; D009355:Neomycin / Q000627:therapeutic use; D009883:Ophthalmic Solutions / Q000627:therapeutic use; D010672:Phenytoin / Q000009:adverse effects*; D011113:Polymyxins / Q000627:therapeutic use; D012640:Seizures / Q000188:drug therapy; D012737:Sex Factors; D013262:Stevens-Johnson Syndrome / Q000139:chemically induced*; D013997:Time Factors; D014449:Tyrothricin / Q000627:therapeutic use; D014786:Vision Disorders / Q000628:therapy
D004338:Drug Combinations; D009883:Ophthalmic Solutions; D011113:Polymyxins; D014449:Tyrothricin; D010672:Phenytoin; D001285:Atropine; D008747:Methylcellulose; D009355:Neomycin